B-Cell Maturation Antigen
"B-Cell Maturation Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily found on mature B-LYMPHOCYTES. It has specificity for B CELL ACTIVATING FACTOR and TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D053301
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.226
|
| Concept/Terms |
B-Cell Maturation Antigen- B-Cell Maturation Antigen
- B Cell Maturation Antigen
- Maturation Antigen, B-Cell
- Receptors, Tumor Necrosis Factor, Member 17
- Tumor Necrosis Factor Receptor Superfamily, Member 17
- B Cell Maturation Protein A
- BCMA Protein
|
Below are MeSH descriptors whose meaning is more general than "B-Cell Maturation Antigen".
Below are MeSH descriptors whose meaning is more specific than "B-Cell Maturation Antigen".
This graph shows the total number of publications written about "B-Cell Maturation Antigen" by people in this website by year, and whether "B-Cell Maturation Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 2 | 2 |
| 2024 | 2 | 0 | 2 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "B-Cell Maturation Antigen" by people in Profiles.
-
Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea. Blood. 2026 May 07; 147(19):2215-2225.
-
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. Leuk Lymphoma. 2024 12; 65(12):1789-1800.
-
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024 May; 59(5):647-652.
-
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023 01; 20(1):49-62.
-
Impact of Manufacturing Procedures on CAR T Cell Functionality. Front Immunol. 2022; 13:876339.